KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $977.0 million.

  • Bristol Myers Squibb's Depreciation & Amortization (CF) fell 4803.19% to $977.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.0 billion, marking a year-over-year decrease of 5821.88%. This contributed to the annual value of $4.0 billion for FY2025, which is 5821.88% down from last year.
  • Bristol Myers Squibb's Depreciation & Amortization (CF) amounted to $977.0 million in Q4 2025, which was down 4803.19% from $1.0 billion recorded in Q3 2025.
  • Over the past 5 years, Bristol Myers Squibb's Depreciation & Amortization (CF) peaked at $2.7 billion during Q3 2021, and registered a low of $977.0 million during Q4 2025.
  • In the last 5 years, Bristol Myers Squibb's Depreciation & Amortization (CF) had a median value of $2.5 billion in 2022 and averaged $2.2 billion.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 771.09% in 2021, then tumbled by 6105.55% in 2025.
  • Over the past 5 years, Bristol Myers Squibb's Depreciation & Amortization (CF) (Quarter) stood at $2.6 billion in 2021, then dropped by 2.25% to $2.5 billion in 2022, then dropped by 2.26% to $2.5 billion in 2023, then dropped by 23.7% to $1.9 billion in 2024, then plummeted by 48.03% to $977.0 million in 2025.
  • Its Depreciation & Amortization (CF) was $977.0 million in Q4 2025, compared to $1.0 billion in Q3 2025 and $1.0 billion in Q2 2025.